The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study
Open accessAbstract
Importance: Entecavir and tenofovir disoproxil fumarate have comparable efficacy in achieving surrogate end points, including virologic response, and are equally recommended as first-line treatments for patients with chronic hepatitis B (CHB). However, it is unclear whether treatment with these drugs is associated with equivalent clinical outcomes, especially development of hepatocellular carcinoma (HCC). Objective: To compare entecavir and tenofovir in terms of the risk of HCC and death or liver transplant in patients with CHB infection. Design, Setting, and Participants: A nationwide historical population cohort study involving treatment-naive adult patients with CHB who started treatment with entecavir (n = 11 464) or tenofovir disoproxil fumarate (n = 12 692) between January 1, 2012, and December 31, 2014, using data from the Korean National Health Insurance Service database. As validation, a hospital cohort of patients with CHB treated with entecavir (n = 1560) or tenofovir (n = 1141) in a tertiary referral center between January 1, 2010, and December 31, 2016, were analyzed. Nationwide cohort data were retrieved from January 1, 2010, to December 31, 2016, and hospital cohort data from January 1, 2010, to October 31, 2017. Main Outcomes and Measures: Cumulative incidence rates of HCC and death and transplant rates. Results: Among the population cohort of 24 156, the mean (SD) age was 48.9 (9.8) years, and 15 120 patients (62.6%) were male. Among the hospital cohort of 2701, the mean (SD) age was 48.8 (10.5) years and 1657 patients (61.3%) were male. In the population cohort, the annual incidence rate of HCC was significantly lower in the tenofovir group (0.64 per 100 person-years [PY]) than in the entecavir group (1.06 per 100 PY). By multivariable-adjusted analysis, tenofovir therapy was associated with a significantly lower risk of HCC (hazard ratio [HR], 0.61; 95% CI, 0.54-0.70) and all-cause mortality or transplant (HR, 0.77; 95% CI, 0.65-0.92) compared with entecavir. The tenofovir group also showed a significantly lower risk of HCC in the 10 923-pair propensity score-matched population cohort (HR, 0.62; 95% CI, 0.54-0.70) and 869-pair propensity score-matched hospital cohort (HR, 0.68; 95% CI, 0.46-0.99) compared with the entecavir group. Conclusions and Relevance: This study suggests that tenofovir treatment was associated with a significantly lower risk of HCC compared with entecavir treatment in a population-based cohort of adults with CHB; these findings were validated in a hospital cohort. Given the poor prognosis of patients with HCC, these findings may have considerable clinical implications in prevention of this cancer in patients with CHB infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Self-citationEASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
Lampertico, P., Agarwal, K., Berg, T., Buti, M., Janssen, H. L. A., Papatheodoridis, G., Zoulim, F., & Tacke, F. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.021 · Cited by 5,391
Terrault, N. A., Lok, A. S. F., McMahon, B. J., Chang, K., Hwang, J. P., Jonas, M. M., Brown, R. S., Bzowej, N. H., & Wong, J. B. (2018) · Hepatology · doi:10.1002/hep.29800 · Cited by 4,306
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
Chen, C.-J. (2006) · JAMA · doi:10.1001/jama.295.1.65 · Cited by 3,140
Schweitzer, A., Horn, J., Mikolajczyk, R. T., Krause, G., & Ott, J. J. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61412-x · Cited by 2,742
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
Liaw, Y.-F., Sung, J. J. Y., Chow, W. C., Farrell, G., Lee, C.-Z., Yuen, H., Tanwandee, T., Tao, Q.-M., Shue, K., Keene, O. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033364 · Cited by 2,266
Razavi-Shearer, D., Gamkrelidze, I., Nguyen, M. H., Chen, D.-S., Van Damme, P., Abbas, Z., Abdulla, M., Abou Rached, A., Adda, D., Aho, I., et al. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30056-6 · Cited by 1,661
Self-citationLok, A. S. F., McMahon, B. J., Brown, R. S., Wong, J. B., Ahmed, A. T., Farah, W., Almasri, J., Alahdab, F., Benkhadra, K., Mouchli, M. A., et al. (2016) · Hepatology · doi:10.1002/hep.28280 · Cited by 552
Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis
WIEMANN, S. U., SATYANARAYANA, A., TSAHURIDU, M., TILLMANN, H. L., ZENDER, L., KLEMPNAUER, J., FLEMMING, P., FRANCO, S., BLASCO, M. A., MANNS, M. P., et al. (2002) · The FASEB Journal · doi:10.1096/fj.01-0977com · Cited by 527 · cited 1×
“These data raise concern about the carcinogenic potential of entecavir even at clinical doses during longterm treatment, especially inpatientswith cirrhosiswhohave increased chromosomal instability of hepatocytes.(26,27) Nevertheless, given that HBV replication itself is a strong independent risk factor forHCC,assessi…”
BackgroundRequirements for global elimination of hepatitis B: a modelling study
Nayagam, S., Thursz, M., Sicuri, E., Conteh, L., Wiktor, S., Low-Beer, D., & Hallett, T. B. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30204-3 · Cited by 373
Papatheodoridis, G. V., Idilman, R., Dalekos, G. N., Buti, M., Chi, H., van Boemmel, F., Calleja, J. L., Sypsa, V., Goulis, J., Manolakopoulos, S., et al. (2017) · Hepatology · doi:10.1002/hep.29320 · Cited by 301
Woo, G., Tomlinson, G., Nishikawa, Y., Kowgier, M., Sherman, M., Wong, D. K. H., Pham, B., Ungar, W. J., Einarson, T. R., Heathcote, E. J., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.06.042 · Cited by 259
Kim, W. R., Loomba, R., Berg, T., Aguilar Schall, R. E., Yee, L. J., Dinh, P. V., Flaherty, J. F., Martins, E. B., Therneau, T. M., Jacobson, I., et al. (2015) · Cancer · doi:10.1002/cncr.29537 · Cited by 212
Antitumor Activity of IFN-λ in Murine Tumor Models
Sato, A., Ohtsuki, M., Hata, M., Kobayashi, E., & Murakami, T. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.12.7686 · Cited by 195
Lim, Y., Han, S., Heo, N., Shim, J. H., Lee, H. C., & Suh, D. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.02.033 · Cited by 151
Self-citationAntitumor activity of Type I and Type III interferons in BNL hepatoma model
Abushahba, W., Balan, M., Castaneda, I., Yuan, Y., Reuhl, K. R., Raveche, E. S., de la Torre, A., Lasfar, A., & Kotenko, S. V. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0831-3 · Cited by 122
Kim, H., Jee, Y. M., Song, B., Shin, J. W., Yang, S. H., Mun, H.-S., Kim, H. J., Oh, E.-J., Yoon, J., Kim, Y. J., et al. (2006) · Intervirology · doi:10.1159/000096313 · Cited by 121
Self-citationWilkens, L., Flemming, P., Gebel, M., Bleck, J. S., Terkamp, C., Wingen, L. U., Kreipe, H. H., & Schlegelberger, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0305817101 · Cited by 97
Varbobitis, I. C., & Papatheodoridis, G. (2016) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2016.0045 · Cited by 96
Ahn, J. C., Lim, J. K., Lee, H. M., Lok, A. S.-F., Nguyen, M. H., Pan, C. Q., Mannalithara, A., Te, H. S., Reddy, K. R., Trinh, H. N., et al. (2016) · The American Journal of Gastroenterology · doi:10.1038/ajg.2016.257 · Cited by 48
Batırel, A. A., Güçlü, E., Arslan, F., Kocak, F., Karabay, O., Ozer, S., Turanlı, M., & Mert, A. (2014) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2014.09.004 · Cited by 42
Choi, K., & Kim, D.-H. (2015) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph120505129 · Cited by 35
Brown, J. A., Pack, L. R., Fowler, J. D., & Suo, Z. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200458s · Cited by 25
Genetic Evidence for Genotoxic Effect of Entecavir, an Anti-Hepatitis B Virus Nucleotide Analog
Jiang, L., Wu, X., He, F., Liu, Y., Hu, X., Takeda, S., & Qing, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147440 · Cited by 19
Cited by
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 343
Predictors of early and late hepatocellular carcinoma recurrence
Nevola, R., Ruocco, R., Criscuolo, L., Villani, A., Alfano, M., Beccia, D., Imbriani, S., Claar, E., Cozzolino, D., Sasso, F. C., et al. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i8.1243 · Cited by 274
Jang, T.-Y., Ho, C.-C., Wu, C.-D., Dai, C.-Y., & Chen, P.-C. (2023) · Medicine · doi:10.1097/md.0000000000034276 · Cited by 10
“[30] Some hepatolo-gists suggest NA therapy only if HBV DNA is more than 2000 IU/mL. [31] It has been controversial whether patients need NAs if HBV DNA is less than 2000 IU/mL in non-cirrhotic patients.”
Metadata
- Authors
- Choi, J., Kim, H. J., Lee, J., Cho, S., Ko, M. J., & Lim, Y.-S.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2019-01-01
- Volume
- 5
- Issue
- 1
- Pages
- 30
- ISSN
- 2374-2437 (ISSN-L)
- OpenAlex
- W2893123471
- Cited by
- 282
- References
- 25
- FWCI
- 24.20
- Type
- journal article
- Language
- en
- Status
- Retracted
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.